Vertex Pharmaceuticals Incorporated (BVMF:VRTX34)

Market Cap	597.88B
Revenue (ttm)	62.48B
Net Income (ttm)	19.59B
Shares Out	n/a
EPS (ttm)	75.80
PE Ratio	30.53
Forward PE	21.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	73
Open	602.25
Previous Close	606.14
Day's Range	590.23 - 602.25
52-Week Range	497.63 - 735.49
Beta	0.31
RSI	42.29
Earnings Date	Feb 2, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: VRTX34

Financial Performance

Financial numbers in USD